Carlton Fields attorney Gregory Boulos authored an article in the
Cannabis Industry Journal about recent developments in regulation of cannabis products. The article, “CBD Health Claims Spur FDA Warning & Product Seizure Threats,” discusses the U.S. Food and Drug Administration’s recent warning letter to the CBD product company Curaleaf. The FDA questioned several of the company’s claims about its products’ effect on users’ health.
“Eliminating [regulatory] risks is impossible, but addressing them upfront before a product launch, regulatory crackdown, or lawsuit is considerably less expensive than dealing with costly litigation or government seizure of entire inventories,” Boulos wrote. “Developing in-depth institutional knowledge regarding the state-of-the-art scientific research on your product is a must.”
READ:
Cannabis Industry Journal, “
CBD Health Claims Spur FDA Warning & Product Seizure Threats”